426 related articles for article (PubMed ID: 33690816)
61. Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies.
Xu X; Sun Q; Liang X; Chen Z; Zhang X; Zhou X; Li M; Tu H; Liu Y; Tu S; Li Y
Front Immunol; 2019; 10():2664. PubMed ID: 31798590
[TBL] [Abstract][Full Text] [Related]
62. CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.
Qin H; Dong Z; Wang X; Cheng WA; Wen F; Xue W; Sun H; Walter M; Wei G; Smith DL; Sun X; Fei F; Xie J; Panagopoulou TI; Chen CW; Song JY; Aldoss I; Kayembe C; Sarno L; Müschen M; Inghirami GG; Forman SJ; Kwak LW
Sci Transl Med; 2019 Sep; 11(511):. PubMed ID: 31554741
[TBL] [Abstract][Full Text] [Related]
63. Treatment of CML-transformed B Cell Acute Lymphoblastic Leukemia (B-ALL) in Adults with Anti-CD19 Chimeric Antigen Receptor T Cell (CAR T) Therapy.
Liu F; Sha S; Ma G; Su Y; Xiong Y; He G; Li Y; Hanes WM; Tse W
Stem Cell Rev Rep; 2020 Dec; 16(6):1356-1358. PubMed ID: 32840736
[No Abstract] [Full Text] [Related]
64. Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients.
Wang Y; Li H; Song X; Qi K; Cheng H; Cao J; Shi M; Yan Z; Jing G; Pan B; Sang W; Wang X; Zhao K; Chen C; Chen W; Zheng J; Li Z; Xu K
Int J Lab Hematol; 2021 Apr; 43(2):250-258. PubMed ID: 33112046
[TBL] [Abstract][Full Text] [Related]
65. The TCF-1 and LEF-1 transcription factors have cooperative and opposing roles in T cell development and malignancy.
Yu S; Zhou X; Steinke FC; Liu C; Chen SC; Zagorodna O; Jing X; Yokota Y; Meyerholz DK; Mullighan CG; Knudson CM; Zhao DM; Xue HH
Immunity; 2012 Nov; 37(5):813-26. PubMed ID: 23103132
[TBL] [Abstract][Full Text] [Related]
66. CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo.
Chicaybam L; Abdo L; Carneiro M; Peixoto B; Viegas M; de Sousa P; Fornazin MC; Spago MC; Albertoni Laranjeira AB; de Campos-Lima PO; Nowill A; Barros LRC; Bonamino MH
Hum Gene Ther; 2019 Apr; 30(4):511-522. PubMed ID: 30793967
[TBL] [Abstract][Full Text] [Related]
67. Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.
Badar T; Shah NN
Curr Treat Options Oncol; 2020 Feb; 21(2):16. PubMed ID: 32025828
[TBL] [Abstract][Full Text] [Related]
68. CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia.
Wang X; Dong Z; Awuah D; Chang WC; Cheng WA; Vyas V; Cha SC; Anderson AJ; Zhang T; Wang Z; Szymura SJ; Kuang BZ; Clark MC; Aldoss I; Forman SJ; Kwak LW; Qin H
Leukemia; 2022 Apr; 36(4):1015-1024. PubMed ID: 35039637
[TBL] [Abstract][Full Text] [Related]
69. Enhancing CD19 Chimeric Antigen Receptor T Cells Through Memory-Enriched T Cells.
El Marabti E; Abdel-Wahab O
Clin Cancer Res; 2023 Feb; 29(4):694-696. PubMed ID: 36507801
[TBL] [Abstract][Full Text] [Related]
70. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.
Singh H; Figliola MJ; Dawson MJ; Huls H; Olivares S; Switzer K; Mi T; Maiti S; Kebriaei P; Lee DA; Champlin RE; Cooper LJ
Cancer Res; 2011 May; 71(10):3516-27. PubMed ID: 21558388
[TBL] [Abstract][Full Text] [Related]
71. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
72. CD19 CAR T cell product and disease attributes predict leukemia remission durability.
Finney OC; Brakke HM; Rawlings-Rhea S; Hicks R; Doolittle D; Lopez M; Futrell RB; Orentas RJ; Li D; Gardner RA; Jensen MC
J Clin Invest; 2019 May; 129(5):2123-2132. PubMed ID: 30860496
[TBL] [Abstract][Full Text] [Related]
73. The what, when and how of CAR T cell therapy for ALL.
Frey N
Best Pract Res Clin Haematol; 2017 Sep; 30(3):275-281. PubMed ID: 29050700
[TBL] [Abstract][Full Text] [Related]
74. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
[TBL] [Abstract][Full Text] [Related]
75. Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity.
Zanetti SR; Romecin PA; Vinyoles M; Juan M; Fuster JL; Cámos M; Querol S; Delgado M; Menendez P
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32868394
[TBL] [Abstract][Full Text] [Related]
76. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression.
Fousek K; Watanabe J; Joseph SK; George A; An X; Byrd TT; Morris JS; Luong A; Martínez-Paniagua MA; Sanber K; Navai SA; Gad AZ; Salsman VS; Mathew PR; Kim HN; Wagner DL; Brunetti L; Jang A; Baker ML; Varadarajan N; Hegde M; Kim YM; Heisterkamp N; Abdel-Azim H; Ahmed N
Leukemia; 2021 Jan; 35(1):75-89. PubMed ID: 32205861
[TBL] [Abstract][Full Text] [Related]
77. Sequential treatment with aT19 cells generates memory CAR-T cells and prolongs the lifespan of Raji-B-NDG mice.
Chen R; Wang M; Liu Q; Wu J; Huang W; Li X; Du B; Xu Q; Duan J; Jiao S; Lee HS; Jung NC; Lee JH; Wang Y; Wang Y
Cancer Lett; 2020 Jan; 469():162-172. PubMed ID: 31634527
[TBL] [Abstract][Full Text] [Related]
78. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
[TBL] [Abstract][Full Text] [Related]
79. CAR-T cell therapy in paediatric acute lymphoblastic leukaemia - past, present and future.
Rogosic S; Ghorashian S
Br J Haematol; 2020 Nov; 191(4):617-626. PubMed ID: 33190266
[TBL] [Abstract][Full Text] [Related]
80. Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.
Zhang C; Kong PY; Li S; Chen T; Ni X; Li Y; Wang M; Liu Y; Gao L; Gao L; Peng XG; Sun AH; Wang P; Yang Z; Zhang X; Qian C
J Immunother; 2018; 41(6):306-311. PubMed ID: 29864079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
